Skip to main content

Want a detailed portfolio tracker?

Performance analysis of Cadrenal Therapeutics (CVKD)

Annual Return

Over the past 3 years, CVKD has had an average annual return of -51.29%, underperforming the benchmark SPY, which returned +19.31% annual.

Since Jan 20, 2023, CVKD has had an average annual return of -62.02%, underperforming the benchmark SPY, which returned +21.22% annual.

2026202520242023
-69.19%-53.22%+30.57%-82.04%

Monthly Return

YearJanFebMarAprMayJunJulAugSepOctNovDecAnnually Total
2026+2.55%+22.13%-39.74%+30.31%-25.58%-32.75%-37.41%-69.19%
2025+36.42%-3.91%-7.19%-6.87%-18.82%-9.60%-13.54%+24.38%+6.72%-1.21%-31.30%-27.78%-53.22%
2024+145.94%-61.31%-13.34%-27.89%+7.12%-0.26%-7.62%+16.89%+79.30%+24.22%-10.42%-4.60%+30.57%
2023-32.52%-28.42%-29.15%-4.97%+6%+6.32%-43.71%-9.40%-11.66%-35.19%+4.39%+60.79%-82.04%

Drawdown analysis of Cadrenal Therapeutics (CVKD)

The maximum drawdown for the CVKD was -96.62%, occurring on Jul 20, 2026. This drawdown has not yet recovered.

The current CVKD drawdown is -96.62%.

Since Jan 20, 2023 CVKD has experienced the following drawdowns:

  • 50% or more: 1 time
  • 40% or more: 1 time
  • 30% or more: 1 time
  • 20% or more: 1 time
  • 10% or more: 1 time
DepthStartTo BottomBottomTo RecoverEndTotal
-96.62%Jan 20, 2023875Jul 20, 2026OngoingOngoingOngoing